Clinical relevance of T1-S, an oncogene-inducible, secreted glycoprotein of the immunoglobulin superfamily, in node-negative breast cancer.
Axillary lymph node-negative breast cancer patients have a low risk for disease recurrence, and the majority of these patients are cured by surgery alone. However, accurate identification of that 30% of node-negative patients who are at high-risk for relapse and who might therefore benefit from adjuvant systemic therapy has not been possible using traditional histomorphological and clinical prognostic factors alone. Identification of novel tumor-associated molecules may therefore provide a basis for a better understanding of and eventually for an interference with disease progression. We have recently reported on tumor-associated RNA up-regulation of the secreted, soluble T1-S receptor in node-negative breast cancer. In the present study we analyzed the tumor-associated level of the T1-S receptor using semiquantitative immunohistochemistry in a collective of 102 node-negative breast carcinomas to study its clinical relevance. A high T1-S immunoreactivity score indicating T1-S overexpression was observed in 58 of 102 (57%) cases. The T1-S score was independent of the tumor size, type, grade, steroid hormone receptor status, and the proliferation rate determined by monoclonal antibody against KI-67 protein (MIB1) immunohistochemistry. In univariate and multivariate analysis of disease-free survival, a high T1-S score (p = 0.003) and a low MIB1 score (p = 0.001) were the only parameters that were highly significantly associated with an improved disease-free survival period. We conclude that T1-S receptor overexpression is a novel and independent tumor biological factor that may be associated with reduced progression of lymph node-negative breast cancer.
Institut für Allgemeine Pathologie und Pathologische Anatomie, Munich, Germany. prechtel@lrz.tum.de
D
D
Prechtel
N
N
Harbeck
U
U
Berger
H
H
Höfler
A K
AK
Werenskiold
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018450:Disease Progression; D005260:Female; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D011237:Predictive Value of Tests; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D015996:Survival Rate
D014408:Biomarkers, Tumor; D006023:Glycoproteins; D007136:Immunoglobulins; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C422066:T1-S protein, human